More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.23B
EPS
-5.99
P/E ratio
--
Price to sales
25.75
Dividend yield
--
Beta
1.454082
Previous close
$36.44
Today's open
$36.31
Day's range
$35.41 - $36.50
52 week range
$33.40 - $109
show more
CEO
Howard W. Robin
Employees
63
Headquarters
San Francisco, CA
Exchange
NASDAQ Capital Market
Shares outstanding
34214683
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Nektar Therapeutics (NKTR) Presents at UBS Global Biopharma Conference 2026 Transcript
Nektar Therapeutics ( NKTR ) UBS Global Biopharma Conference 2026 November 17, 2026 6:20 AM EST Company Participants Jonathan Zalevsky - Senior VP and Chief Research & Development Officer Conference Call Participants Alice Nettleton Presentation Alice Nettleton Good morning, everyone. Welcome to the next session at the UBS Global Biopharma Conference.
Seeking Alpha • Nov 17, 2026

Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 13, 2026

NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down
Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.
Zacks Investment Research • Nov 13, 2026

What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call
Nektar Therapeutics NASDAQ: NKTR said it has initiated three Phase III studies of its experimental drug rezpegaldesleukin, or REZPEG, in atopic dermatitis and expects to begin a pivotal alopecia areata study in December, earlier than previously planned.
MarketBeat • Nov 13, 2026

Nektar Therapeutics Announces Third Quarter 2026 Financial Results
SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025.
PRNewsWire • Nov 12, 2026

Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $2.16. This compares to a loss of $1.85 per share a year ago.
Zacks Investment Research • Nov 13, 2026

Nektar Therapeutics to Participate in Two Investor Conferences in November
SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS Global Biopharma Conference Format: Fireside Chat and 1x1 meetings Fireside Chat Date: Tuesday, November 17, 2026 Fireside Chat Time: 11:20 – 11:50 a.m.
PRNewsWire • Nov 11, 2026

Nektar Therapeutics: Focus Returns To The Strengths Of The Company
NKTR's rezpegaldesleukin is now in phase 3 trials in atopic dermatitis, but there is additional data from the company's phase 2b REZOLVE-AD trial expected in Q1'27. The market focus has shifting back to atopic dermatitis could be considered bullish, since the drug has impressed more in that indication previously. By comparison, an early October update from the alopecia areata trial, REZOLVE-AA, was met with selling.
Seeking Alpha • Oct 30, 2026

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 29, 2026

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.
PRNewsWire • Oct 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Nektar Therapeutics commission-free¹. Build wealth for the long term using automated trading and transfers.